Business
Voyageur Pharmaceuticals Ltd. Completes Comparative Studies of its SmoothX(R) Contrast Media Confirming Product Superiority, and announces Option Grant and AGM Date
(TheNewswire) Calgary, Alberta – TheNewswire - April 4, 2023 - Voyageur ...
About this update from Voyageur Pharmaceuticals Ltd
[{"type":"text","content":"Voyageur Pharmaceuticals Ltd. Completes Comparative Studies of its SmoothX(R) Contrast Media Confirming Product Superiority, and announces Option Grant and AGM Date\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Calgary, Alberta –\n \n \n TheNewswire -\n \n \n April 4, 2023 -\n \n \n Voyageur Pharmaceuticals Ltd.\n \n \n (TSXV:VM)\n \n \n (\n \n \n OTC\n \n \n :VYYRF) (the\n\"Company\" or \"Voyageur\") announces that it has\ncompleted comparative studies of SmoothX® versus Readi-Cat\n \n \n \n \n ®\n \n \n 2%\nwith taste test and Computed Tomography (CT) scans on patients.\nResults of the double-blind testing showed that SmoothX® was favoured\non drinkability and taste by\n \n \n 75%\n \n \n of patients compared to the competing\nproduct. The computed tomography scans were performed by Canada\nDiagnostics in Calgary, Alberta and resulted in equivalent performance\nto the current drug.\n \n \n \n \n Our team of experts is currently preparing a medical\nwhite paper that will provide an in-depth analysis of the studies and\nvaluable insights into the effectiveness of SmoothX to educate and\ninform doctors and medical staff about the benefits of SmoothX® for\nabdominal CT diagnostic imaging procedures.  This paper is a critical\npart of our overall preparation for market launch, and we are\nconfident that it will showcase the rigorous research and development\nthat has gone into bringing this product to fruition.\n \n \n \n \n Voyageur is expanding its product line by advancing the\ndevelopment of an additional four barium contrast products, for which\nthe company have already obtained Health Canada licenses. The company\nplans to submit additional new generic product lines to Health Canada\nfor product licenses, including multiple barium swallow products for\nthe diagnosis of dysphagia. This market has been identified as a\npotential high growth area, with range estimated as being as high as\n22% of the population over 50 years of age affected by dysphagia.\nVoyageur plans to have a total of 13 barium contrast product lines\navailable for the Canadian and US markets. The National Foundation of\nSwallowing Disorders states:\n \n \n \n \n “The prevalence of dysphagia is unknown, but\n \n \n Epidemiologic studies\nindicate that...